Drug Profile
Roducitabine - Ocuphire Pharma
Alternative Names: FCPEC; Fluorocyclopentenylcytosine; NGC-Gemcitabine; PCS-3117; RX 3117; TV-1360Latest Information Update: 05 Dec 2023
Price :
$50
*
At a glance
- Originator Rexahn Pharmaceuticals
- Developer Ocuphire Pharma; Processa Pharmaceuticals; Rexahn Pharmaceuticals
- Class Antineoplastics; Cyclopentanes; Fluorinated hydrocarbons; Nucleosides; Pyrimidine nucleosides; Small molecules
- Mechanism of Action DNA synthesis inhibitors; RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Bladder cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 29 Nov 2023 Processa Pharmaceuticals expects discussion with FDA for phase IIb/IIIa trial in first half of 2024
- 07 Sep 2023 Phase-II clinical trials in Solid tumours in USA (PO)
- 05 Apr 2023 Processa Pharmaceuticals plans to discuss with the US FDA regarding the design of phase IIB trial and Project Optimus, in 2023